

DAFTAR PUSTAKA

- Abraham, B. P., & Kane, S. (2012). Fecal Markers: Calprotectin and Lactoferrin. *Gastroenterology Clinics of North America*, 41(2), 483–495. <https://doi.org/10.1016/j.gtc.2012.01.007>
- Aqbal, D., Assya, A., Bolloso, E., & Angerio, A. (2007). The Role of C- Reactive Protein in Inflammatory Bowel Disease. *GUJHS*, 4(1).
- Ardesia, M., Ferlazzo, G., Fries, W., & Šebeková, K. (2015). *Vitamin D and inflammatory bowel disease. 2015*. <https://doi.org/10.1155/2015/470805>
- Arrieta, M. C., Bistriz, L., & Meddings, J. B. (2006). Alterations in intestinal permeability. *Gut*, 55(10), 1512–1520. <https://doi.org/10.1136/gut.2005.085373>
- Assche, G. Van, & Rutgeerts, P. (2004). C-Reactive Protein as a Marker for Inflammatory. *Proteins*, 10(5), 661–665.
- Batista, L., Ruiz, L., Ferrer, C., Zabana, Y., Aceituno, M., Arau, B., Andújar, X., Esteve, M., & Fernández-Bañares, F. (2019). Usefulness of fecal calprotectin as a biomarker of microscopic colitis in a cohort of patients with chronic watery diarrhoea of functional characteristics. *Digestive and Liver Disease*, 51(12), 1646–1651. <https://doi.org/10.1016/j.dld.2019.07.002>
- Bertsch, T., Triebel, J., Bollheimer, C., Christ, M., Sieber, C., Fassbender, K., & Heppner, H. J. (2015). C-reaktives Protein und die Akute-Phase-Reaktion bei geriatrischen Patienten. *Zeitschrift Fur Gerontologie Und Geriatrie*, 48(7), 595–600. <https://doi.org/10.1007/s00391-015-0938-4>
- Bjarnason, I. (2017). The use of fecal calprotectin in inflammatory bowel disease. In *Gastroenterology and Hepatology* (Vol. 13, Issue 1, pp. 53–56).
- Boland, K., & Nguyen, G. C. (2017). Microscopic colitis: A review of collagenous and lymphocytic colitis. *Gastroenterology and Hepatology*, 13(11), 671–677.
- Burri, E., & Christoph, B. (2011). Inflammation Fae cal cal pro tec tin in the diagnosis of in fl am ma to ry bowel di sea se. *Biochemia Medica* 2011;21(3):245–53, 21(3), 245–253.
- Ciccia, F., Ferrante, A., & Triolo, G. (2016). Intestinal dysbiosis and innate immune responses in axial spondyloarthritis. *Current Opinion in Rheumatology*, 28(4), 352–358. <https://doi.org/10.1097/BOR.0000000000000296>
- Cioffi, M. (2015). Laboratory markers in ulcerative colitis: Current insights and future advances. *World Journal of Gastrointestinal Pathophysiology*, 6(1), 13. <https://doi.org/10.4291/wjgp.v6.i1.13>
- Clara, A. P. H. S., Magnago, F. D., Ferreira, J. N., & Grillo, T. G. (2016). Microscopic colitis: A literature review. *Revista Da Associacao Medica*

- Brasileira*, 62(9), 895–900. <https://doi.org/10.1590/1806-9282.62.09.895>
- D'Angelo, F., Felley, C., & Frossard, J. L. (2017). Calprotectin in Daily Practice: Where Do We Stand in 2017? *Digestion*, 95(4), 293–301. <https://doi.org/10.1159/000476062>
- Dhaliwal, A., Zeino, Z., Tomkins, C., Cheung, M., Nwokolo, C., Smith, S., Harmston, C., & Arasaradnam, R. P. (2015). Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? *Frontline Gastroenterology*, 6(1), 14–19. <https://doi.org/10.1136/flgastro-2013-100420>
- Firmansyah, M. A. (2017). *Perkembangan Terkini Diagnosis dan Penatalaksanaan Inflammatory Bowel* *Perkembangan Terkini Diagnosis dan Penatalaksanaan Inflammatory Bowel Disease*. 40(June 2013), 247–252. <https://www.researchgate.net/publication/321824062>
- Goto, Y., & Ivanov, I. I. (2008). *Intestinal epithelial cells as mediators of the commensal–host immune crosstalk* *Yoshiyuki*. 86(12), 3279–3288. <https://doi.org/10.1007/s11103-011-9767-z>.Plastid
- Guagnozzi, D., Landolfi, S., & Vicario, M. (2016). Towards a new paradigm of microscopic colitis: Incomplete and variant forms. *World Journal of Gastroenterology*, 22(38), 8459–8471. <https://doi.org/10.3748/wjg.v22.i38.8459>
- Hanauer, S. B., & Sandborn, W. (2001). Management of Crohn's disease in adults. *American Journal of Gastroenterology*, 96(3), 635–643. [https://doi.org/10.1016/S0002-9270\(01\)02234-1](https://doi.org/10.1016/S0002-9270(01)02234-1)
- Karasahin, O., Tasar, P. T., Timur, O., Yıldırım, F., Binici, D. N., & Sahin, S. (2018). The value of C-reactive protein in infection diagnosis and prognosis in elderly patients. *Aging Clinical and Experimental Research*, 30(6), 555–562. <https://doi.org/10.1007/s40520-017-0821-9>
- Kyle, B. D., Agbor, T. A., Sharif, S., Chauhan, U., Marshall, J., Halder, S. L. S., Ip, S., & Khan, W. I. (2020). Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results. *Journal of the Canadian Association of Gastroenterology*, Xx, 1–7. <https://doi.org/10.1093/jcag/gwaa009>
- López-Muñoz, P., Beltrán, B., Sáez-González, E., Alba, A., Nos, P., & Iborra, M. (2019). Influence of vitamin D deficiency on inflammatory markers and clinical disease activity in IBD patients. *Nutrients*, 11(5). <https://doi.org/10.3390/nu11051059>
- MacDonald, T. T., & Monteleone, G. (2005). Immunity, inflammation, and allergy in the gut. *Science*, 307(5717), 1920–1925. <https://doi.org/10.1126/science.11106442>
- McMahon, C. W., & Chhabra, R. (2018). The role of fecal calprotectin in investigating digestive disorders. *Journal of Laboratory and Precision*

- Medicine*, 3, 19–19. <https://doi.org/10.21037/jlpm.2018.02.03>
- Mosli, M. H., Zou, G., Garg, S. K., Feagan, S. G., MacDonald, J. K., Chande, N., Sandborn, W. J., & Feagan, B. G. (2015). C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. *American Journal of Gastroenterology*, 110(6), 802–819. <https://doi.org/10.1038/ajg.2015.120>
- MU, A., & M, A. (2014). Microscopic Colitis: An Overview. *Interdisciplinary Journal of Microinflammation*, 01(01), 1–5. <https://doi.org/10.4172/ijm.1000108>
- Mumolo, M. G., Bertani, L., Ceccarelli, L., Laino, G., Fluri, G. Di, Albano, E., Tapete, G., & Costa, F. (2018). From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. *World Journal of Gastroenterology*, 24(33), 3681–3694. <https://doi.org/10.3748/wjg.v24.i33.3681>
- Münch, A., Sanders, D. S., Molloy-Bland, M., & Hungin, A. P. S. (2019). Undiagnosed microscopic colitis: A hidden cause of chronic diarrhoea and a frequently missed treatment opportunity. *Frontline Gastroenterology*, 1–7. <https://doi.org/10.1136/flgastro-2019-101227>
- Natalie, W., & Sherwood, R. (2016). Fecal calprotectin in inflammatory bowel disease. *Clinical and Experimental Gastroenterology*, 9, 21–29.
- Nyhlin, N., Bohr, J., Eriksson, S., & Tysk, C. (2008). Microscopic colitis: A common and an easily overlooked cause of chronic diarrhoea. In *European Journal of Internal Medicine* (Vol. 19, Issue 3, pp. 181–186). <https://doi.org/10.1016/j.ejim.2008.01.001>
- Okumura, R., & Takeda, K. (2017). Roles of intestinal epithelial cells in the maintenance of gut homeostasis. *Experimental and Molecular Medicine*, 49(5), e338-8. <https://doi.org/10.1038/emm.2017.20>
- Olesen, M., Eriksson, S., Bohr, J., Järnerot, G., & Tysk, C. (2004). Microscopic colitis: A common diarrhoeal disease. An epidemiological study in Örebro, Sweden, 1993-1998. *Gut*, 53(3), 346–350. <https://doi.org/10.1136/gut.2003.014431>
- Pelaseyed, T., Bergström, J. H., Gustafsson, J. K., Ermund, A., Birchenough, G. M., Schütte, A., Post, S. Van Der, Svensson, F., & Rodríguez, A. M. (2015). Interact With the Immune System. *Immunological Reviews*, 260(1), 8–20. <https://doi.org/10.1111/imr.12182>
- Pisani, L. F., Tontini, G. E., Marinoni, B., Villanacci, V., Bruni, B., Vecchi, M., & Pastorelli, L. (2017). Biomarkers and microscopic colitis: An unmet need in clinical practice. *Frontiers in Medicine*, 4(MAY), 1–11. <https://doi.org/10.3389/fmed.2017.00054>

- Shor, J., Churrango, G., Hosseini, N., & Marshall, C. (2019). Management of microscopic colitis: Challenges and solutions. *Clinical and Experimental Gastroenterology*, *12*, 111–120. <https://doi.org/10.2147/CEG.S165047>
- Simadibrata, M., & Daldiyono. (2009). No Title. In S. Setiati, I. Alwi, A. Sudoyo, M. Simadibrata, B. Setiyohadi, & A. Syam Fahrizal (Eds.), *Buku Ajar Ilmu Penyakit Dalam* (VI, p. 410). Interna Publisihing.
- Sonnenberg, A., & Genta, R. M. (2012). Geographic distributions of microscopic colitis and inflammatory bowel disease in the United States. *Inflammatory Bowel Diseases*, *18*(12), 2288–2293. <https://doi.org/10.1002/ibd.22932>
- Stephanie, A., & Makmun, D. (2014). Current Diagnostic Approach of Inflammamatory Bowel Disease. *The Indonesian Journal of Gastroenterology , Hepatology and Digestive Endoscopy*, *15*(1), 44–51.
- Townsend, T., Campbell, F., O’Toole, P., & Probert, C. (2019). Microscopic colitis: Diagnosis and management. *Frontline Gastroenterology*, *10*(4), 388–393. <https://doi.org/10.1136/flgastro-2018-101040>
- Vermeire, S., Van Assche, G., & Rutgeerts, P. (2006). Laboratory markers in IBD: Useful, magic, or unnecessary toys? *Gut*, *55*(3), 426–431. <https://doi.org/10.1136/gut.2005.069476>
- von Arnim, U., Wex, T., Ganzert, C., Schulz, C., & Malfertheiner, P. (2016). Fecal calprotectin: A marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. *Clinical and Experimental Gastroenterology*, *9*, 97–103. <https://doi.org/10.2147/CEG.S97701>
- Sukmawati, I. & Harijanto, T., 2004. Optimal Cut-off Value for Obesity: Using Anthropometric Indices to Predict Atherogenic Dyslipidemia in Indonesia Population. *The National Obesity Simposium III*, pp. 87-88
- Vermeire, S., Van Assche, G., & Rutgeerts, P. (2006). Laboratory markers in IBD: Useful, magic, or unnecessary toys? *Gut*, *55*(3), 426–431. <https://doi.org/10.1136/gut.2005.069476>
- Von Arnim, U., Wex, T., Ganzert, C., Schulz, C., & Malfertheiner, P. (2016). Fecal calprotectin: A marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. *Clinical and Experimental Gastroenterology*, *9*, 97–103. <https://doi.org/10.2147/CEG.S97701>
- Zammit S.C., Schembri J., Pisani A., *et al.* (2018). Vitamin D and Ulcerative Colitis: Is There a Relationship with Disease Extent?. *Digestive Disease* pg 1-6